Cleveland Clinic Receives $2.9 Million for Additional Research on Emerging Tick-borne Virus Pathogen
Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).
Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development
In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.
First Research Published Using Cleveland Clinic’s COVID-19 Study Samples Provides Glimpse into Potential New Treatments
Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.